SKIN RASH TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Skin Rash Treatment Market Size and Trends

The skin rash treatment market is estimated to be valued at USD 3.67 Bn in 2024 and is expected to reach USD 5.70 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

The skin rash treatment market is witnessing an increasing adoption of herbal and homeopathic products due to the rising popularity of natural and Ayurvedic remedies for skin problems.

Discover market dynamics shaping the industry request sample copy

Many natural active ingredients such as calendula, aloe vera, and tea tree oil have gained considerable acceptance in rash treatment. Manufacturers are focusing on developing innovative herbal formulations to cater to the needs of health-conscious consumers and capitalize on the opportunities in this trending space. The market is expected to experience steady growth over the forecast period supported by the growing preference for herbal and Ayurvedic remedies over synthetic drugs.

Rising Prevalence of Skin Allergies

The global incidence of skin allergies and related conditions has been steadily increasing over the past few decades. Various factors such as growing environmental pollution, changes in lifestyle and diets, and excessive exposure to chemicals are thought to be major contributors to this rise. Growing urbanization has also played a role as city living brings people into close contact with numerous allergens and irritants in the air every day. Studies show that many modern households now contain hundreds of potential allergy-triggering substances in products such as cleaning agents, air fresheners, fragranced personal care items, synthetic furnishings, etc.

At the same time, growing awareness about various skin conditions has led to more diagnoses. Conditions which were previously undiagnosed or ignored are now being recognized and treated. This is especially true in developing regions where medical infrastructure and diagnostic capabilities are improving. Changing demographics too have impacted prevalence figures, with senior citizens and younger individuals showing higher rates of some types of allergic skin conditions. The pharmaceutical industry has also done an effective job in educating the public about various skin issues through health campaigns.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Adoption of Natural and Herbal Therapies

Increasing consumer preference for natural health solutions without artificial or synthetic ingredients is a global trend that is significantly impacting the skin rash treatment market. More people are turning to herbal remedies, Ayurvedic formulations and other traditional healing practices to manage various kinds of skin issues. This shift is being driven by a desire to avoid harsh chemicals, growing distrust of conventional medications due to potential side-effects, and a search for remedies that treat the root cause rather than just symptoms. Herbal therapies are also perceived as milder options suitable for sensitive or pediatric skin. 

To learn more about this report, request sample copy

Market Challenges – Low Treatment Adherence:

The skin rash treatment market faces several challenges. Existing medication often leads to low treatment adherence due to undesirable side effects like dryness and irritation. This results in higher relapse rates. Additionally, over-the-counter topical creams provide only temporary relief and do not treat the root cause in many cases. Lack of awareness about newer treatment options also hampers full market potential. Diagnosis is another challenge area as skin rashes can be symptoms of various underlying conditions, requiring differential diagnosis.

Market Opportunities - Development of Novel Drugs:

The development of novel drugs provides a great opportunity in the skin rash treatment market. Skin rashes are very common dermatological conditions that affect people of all ages. Conventional treatment options include topical corticosteroids and antihistamines which provide only temporary relief and their long-term use can cause side effects. There is a need for safer and more effective treatment alternatives that can target the root cause of different types of rashes.

Novel drug development aims to address this unmet need through advancements in pharmaceutical research. Many biotech companies are actively pursuing new drug molecules with novel mechanisms of action such as biologicals targeting specific inflammatory pathways and mediators involved in rash pathogenesis.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Insights, By Treatment Type: Rise in the skin problems drives corticosteroid segment growth

Corticosteroids segment is anticipated to have 41.4% of the market share in 2024, owing to its effectiveness in treating various types of skin rashes. Corticosteroids work by reducing inflammation and easing irritations and allergic reactions on the skin. They are highly effective in temporarily relieving symptoms of many inflammatory and autoimmune-based dermatological conditions such as eczema, psoriasis and contact dermatitis. The rising incidence of such skin problems globally is driving the demand for corticosteroid drugs. According to studies published by Penn Medicine, an academic medical center in March 2022, over 32 million Americans suffer from eczema, while more than 7.5 million Americans suffer from psoriasis. The inability to properly identify causes and prevent flare ups of these conditions makes them recurrent issues. This consistent need for effective treatment options is benefitting the corticosteroid segment. Moreover, many corticosteroid formulations are now available in over-the-counter varieties, increasing their accessibility to a wider population and usage. Along with prescription drugs, this growing availability of OTC corticosteroid products like creams and ointments is supporting segmental growth in the skin rash treatment market.

Insights, By Skin Rash Type: Growing prevalence drives psoriasis segment development

Psoriasis segment is expected to have 26.8% of the market share in 2024. Psoriasis causes patches of abnormal skin that are itchy, scaly and inflamed. Flare ups can happen frequently depending on triggers and cause discomfort affecting daily life. Over time psoriasis can also increase risks of developing other serious health issues. With a significant global patient pool suffering from psoriasis, there exists a continued need for effective treatment and management options. This sustained demand is driving focus and new product development towards the psoriasis segment. Several biologics and other advanced therapies have been introduced in recent years targeted exclusively at psoriasis, helping patients gain better control. Moreover, growing awareness about psoriasis and available treatments has encouraged more patients to seek medication. This is propelling the psoriasis segment growth in the skin rash treatment market.

Insights, By Distribution Channel: Availability drives pharmacies segment growth

Pharmacies segment is expected to have 42.7% of the market share in 2024, owing to widespread availability of pharmacies, both online and offline, along with rising preference for self-treatment. Many common skin conditions are now easily manageable with OTC drugs bought directly from pharmacies without requiring a doctor's prescription. This has led to upsurge in self-treatment culture and direct pharmacy purchases for immediate relief from minor rashes and irritation. The copious choice of OTC skin drugs available off-the-shelf at pharmacies matches diverse consumer needs. Busy lifestyles also favor quick pharmacy solutions over long doctor visits for petty skin issues. The pharmacies segment is further strengthened through recommendations by dermatologists to purchase high-quality OTCs from familiar local pharmacies. Overall, enhanced self-care approaches and pharmacies' active role in efficiently supplying medication correspondingly is stimulating segmental growth in the distribution channel landscape.

Regional Insights

To learn more about this report, request sample copy

The North American region currently dominates the global skin rash treatment market and is expected to have market share of 40.2% in 2024. The large market size can be attributed to high consumer spending on healthcare and significant presence of leading pharmaceutical companies. These companies have been investing heavily in R&D to develop advanced treatment options for various skin rashes. Additionally, North America is a major innovator of new drugs and medical technologies, resulting in a wide variety of prescription and OTC medication options available to consumers in this region. The pricing of skin rash treatments is also comparatively higher in the U.S. and Canada due to strong intellectual property laws that allow manufacturers to recover large R&D costs.

The Asia Pacific region has emerged as the fastest growing market for skin rash treatment in recent years. A rapidly developing healthcare sector and rising living standards have increased consumer spending on personal care and appearance in various Asian countries. The growing cosmetic industry has also augmented the demand for products that treat and prevent skin rashes and imperfections. The vast population and tropical climate that leads to higher instances of skin irritations further support market growth. Additionally, low-cost domestic manufacturers produce affordable generic versions that are increasingly preferred by price-sensitive consumers. Some countries have also eased regulations to allow imports of generic drugs, thereby improving access to a variety options of skin rash medications. The Asia Pacific market is expected to be driven by continued economic prosperity of leading markets like India and China.

Market Report Scope

Skin Rash Treatment Industry News

• In May 2022, Dermavant Sciences, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VTAMA (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. This approval makes VTAMA cream the first and only FDA-approved steroid-free topical medication in its class.
• In June 2022, Galderma, a pharmaceutical company specializing in dermatological treatments announced the availability of EPSOLAY (benzoyl peroxide) Cream, 5% in the U.S. following approval by the U.S. Food and Drug Administration (FDA)
• In September 2022, Regeneron Pharmaceuticals, Inc., a biotechnology company and Sanofi, a multinational pharmaceutical and healthcare company announced that the U.S. Food and Drug Administration (FDA) had approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis

*Definition: The "Skin Rash Treatment Market" refers to the segment of the healthcare industry focused on products and services designed to alleviate the symptoms, treat, and manage rashes on the skin. Skin rashes can be caused by a variety of factors, such as allergies, infections, autoimmune diseases, and irritants. The market encompasses a range of treatment options, including: Topical Medications: Creams, lotions, and ointments containing corticosteroids, antihistamines, antibiotics, or antifungal agents that are applied directly to the skin to reduce inflammation and treat infections. Systemic Medications: Oral or injectable drugs used to treat more severe or widespread skin rashes, such as those caused by systemic conditions like psoriasis or eczema. Natural and Alternative Remedies: Herbal treatments, essential oils, and other natural products that may help soothe skin rashes or promote healing.

Market Segmentation

•  Treatment Type Insights (Revenue, USD BN, 2019 - 2031)
• • Corticosteroids
  • Immunosuppressants
  • Antihistamines
  • Antifungals
  • Others (Antibiotics, etc.)
•  Skin Rash Type Insights (Revenue, USD BN, 2019 - 2031)
  • Contact Dermatitis
  • Atopic Dermatitis (Eczema)
  • Psoriasis
  • Seborrheic Dermatitis
  • Others (Allergic Reactions, etc.)
•  Distribution Channel Insights (Revenue, USD BN, 2019 - 2031)
  • Pharmacies
  • Retail Stores
  • Others (Hypermarkets, etc.)
• Regional Insights (Revenue, USD BN, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • AbbVie
  • Amgen
  • Bristol Myers Squibb
  • Galderma
  • Johnson & Johnson
  • LEO Pharma
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Pvt. Ltd.
  • Teva Pharmaceutical Industries
  • Valeant Pharmaceuticals
  • Mylan N.V.
  • Perrigo Company plc
  • Eli Lilly and Company